- Home
- PRAX vs CGAU Comparison
PRAX vs CGAU Comparison
Compare PRAX & CGAU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAX
- CGAU
- Stock Information
- Founded
- PRAX 2015
- CGAU 2002
- Country
- PRAX United States
- CGAU Canada
- Employees
- PRAX N/A
- CGAU N/A
- Industry
- PRAX Biotechnology: Pharmaceutical Preparations
- CGAU Precious Metals
- Sector
- PRAX Health Care
- CGAU Basic Materials
- Exchange
- PRAX Nasdaq
- CGAU Nasdaq
- Market Cap
- PRAX 1.5B
- CGAU 1.2B
- IPO Year
- PRAX 2020
- CGAU N/A
- Fundamental
- Price
- PRAX $71.55
- CGAU $5.85
- Analyst Decision
- PRAX Strong Buy
- CGAU Buy
- Analyst Count
- PRAX 9
- CGAU 3
- Target Price
- PRAX $146.33
- CGAU $11.00
- AVG Volume (30 Days)
- PRAX 315.5K
- CGAU 840.2K
- Earning Date
- PRAX 11-06-2024
- CGAU 10-31-2024
- Dividend Yield
- PRAX N/A
- CGAU 3.42%
- EPS Growth
- PRAX N/A
- CGAU N/A
- EPS
- PRAX N/A
- CGAU 0.47
- Revenue
- PRAX $1,605,000.00
- CGAU $1,252,073,000.00
- Revenue This Year
- PRAX N/A
- CGAU $16.18
- Revenue Next Year
- PRAX N/A
- CGAU N/A
- P/E Ratio
- PRAX N/A
- CGAU $12.13
- Revenue Growth
- PRAX N/A
- CGAU 29.99
- 52 Week Low
- PRAX $16.08
- CGAU $4.47
- 52 Week High
- PRAX $86.93
- CGAU $7.82
- Technical
- Relative Strength Index (RSI)
- PRAX 50.90
- CGAU 42.01
- Support Level
- PRAX $70.03
- CGAU $5.72
- Resistance Level
- PRAX $73.49
- CGAU $6.06
- Average True Range (ATR)
- PRAX 4.10
- CGAU 0.17
- MACD
- PRAX -0.17
- CGAU 0.02
- Stochastic Oscillator
- PRAX 48.89
- CGAU 28.30
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.
About CGAU Centerra Gold Inc.
Centerra Gold Inc a gold mining and exploration company engaged in the operation, exploration, development, and acquisition of gold properties in Asia, North America, and other markets worldwide. The company manages its reportable operating segments by a combination of geographic location and products. The Kyrgyz Republic segment includes the operations of the Kumtor Gold Project. The Turkish segment represents the development of the OksUt Project. The North America Gold- Copper segment represents the operations of the Mount Milligan Mine. The North America Molybdenum segment includes the operations of the Langeloth processing facility and the care and maintenance activities of the Endako and Thompson Creek Mines.